NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Roche »16/05/2010 [Company watch]
Roche Diagnostics Growing at 50% Rate in China

Roche Diagnostics has been experiencing annual revenue increases of close to 50% per year, and the company expects the large increases to continue, driven by the PRC’s investment into healthcare. Roche Diagnostics thinks China will soon become its fifth largest market, up from eighth last year.

 
Roche Diagnostics has been experiencing annual revenue increases of close to 50% per year, and the company expects the large increases to continue, driven by the PRC’s investment into healthcare. Roche Diagnostics thinks China will soon become its fifth largest market, up from eighth last year. Roche Diagnostics currently claims a 20% share of the global in-vitro diagnostics market, which makes it the largest player in the sector worldwide. It also holds the number one ranking in China. A full 80% of Roche’s IVD products are available in China, and Roche is working on registering many of the remaining products. The revelations were made by Daniel O\'Day, Chief Operating Officer of Roche Diagnostics in an interview with Interfax China (see story). China’s program for extending healthcare involves building new hospitals, which necessitates new immunoassay labs. Immunoassays are the fastest growing sector in the IVD market, according to O’Day. \"We also see tremendous growth potential in other areas like molecular diagnostics, particularly in blood screening and infectious disease monitoring for acquired immunodeficiency syndrome (AIDS) and human papillomavirus (HPV). Tissue diagnostics will likely see growth too as cancer care becomes more widely available in China,\" said O’Day. In the larger Asia-Pacific region, Roche claims a 21% market share in IVD product. The numbers represent an impressive level of revenue: $924 million in 2009, a 25% increase in constant-currency terms. Worldwide, the company’s diagnostic division produced about $9.1 billion, or 20% of Roche’s total revenues. The biggest growth areas were the Asia-Pacific region and Europe, the Middle East and Africa. In China, Roche is in the middle of the process of registering its high-profile tissue diagnostic test for the HER2 gene. If breast or stomach cancer patients exhibit the gene, they are eligible for treatment with Herceptin, an antibody treatment. \"As cardiovascular disease, diabetes and cancers become more common in China, we are also seeing an increase in the use of more medically efficient tests, for instance, Roche Diagnostics\' NT-proBNP test for heart failure,\" O’Day said. The test is an accurate test of heart failure, a condition that is often misdiagnosed. The test can also be used to help a doctor decide if a patient needs to be hospitalized or if a patient is well enough to be discharged. In the US, the American Journal of Cardiology completed a study showing that the NT-proBNP test can reduce the number of cardiac ultrasound tests by 58% and shorten hospitalizations by 12%. Roche Diagnostics Shanghai now has more than 700 employees. It has plans to hire 100 more before the end of this year. As we reported two weeks ago, Roche\'s pharmaceutical division is sticking with its high-end strategy in China, even though China is very receptive to generic drugs

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.